Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Latest News
thumbnail
RegulationsNovo Catalent deal clears regulatory hurdles
Novo Catalent deal clears regulatory hurdles
The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.
Deal-Making
In addition to producing glucagon-like peptide-1 (GLP-1) drugs for an anonymous partner over five years, the Korean firm is consolidating its brands.
Deal-Making
MilliporeSigma to acquire Netherlands-based organoid pioneer HUBMilliporeSigma to acquire Netherlands-based organoid pioneer HUB
The agreement is expected to close by the end of 2024, expanding MilliporeSigma’s service offerings.
Facilities & Capacity
Israeli biomanufacturer Scinai expands into US with CDMO subsidiaryIsraeli biomanufacturer Scinai expands into US with CDMO subsidiary
The company signed Serpin Pharma to support early clinical manufacturing.
Facilities & Capacity
Lonza calls time on capsules as mAbs and CGT drive core CDMO strategyLonza calls time on capsules as mAbs and CGT drive core CDMO strategy
Under its “One Lonza” strategy, the CDMO will exit the capsules space to focus on three business units: Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
Global Markets
The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.
Facilities & Capacity
Diabetes drug firms Sanofi, Novo expand global footprintDiabetes drug firms Sanofi, Novo expand global footprint
Amid the booming demand for diabetes and weight loss drugs, Sanofi and Novo Nordisk have expanded their facilities in China, and Denmark respectively.
Regulations
The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.
Regulations
Vaccine makers sanguine amid threat from US health nominees RFK Jr. and Dr. OzVaccine makers sanguine amid threat from RFK Jr. and Dr. Oz
Pfizer, Merck & Co., and Moderna remain upbeat over future dealings with the US government despite President-elect Trump telling vaccine-sceptic and alternative-medicine proponents to “go wild on health.”
Therapeutic Class
MilliporeSigma to acquire Netherlands-based organoid pioneer HUBMilliporeSigma to acquire Netherlands-based organoid pioneer HUB
The agreement is expected to close by the end of 2024, expanding MilliporeSigma’s service offerings.
Therapeutic Class
CGT Catapult and UCL to develop digital twin for CAR-T manufacturingCGT Catapult and UCL to develop digital twin for CAR-T manufacturing
The London, UK-based organization says new technologies will lead to greater efficiencies and fewer failures.
Upstream & Downstream Processing
CGT Catapult and UCL to develop digital twin for CAR-T manufacturingCGT Catapult and UCL to develop digital twin for CAR-T manufacturing
The London, UK-based organization says new technologies will lead to greater efficiencies and fewer failures.
Facilities & Capacity
Q&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMOQ&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMO
“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.